ANI Pharmaceuticals, Inc.
NASDAQ:ANIPDrug Manufacturers - Specialty & Generic
-$1.42 today
- Market cap
- $1.62B
- Beta
- 0.44
- P/E (TTM)
- 18.5
- EPS (TTM)
- $4.29
Volume 0.29M
Average 0.35M
ANIP Income Tax Expense
Income taxes recognized for the period, including current and deferred tax.
ANI Pharmaceuticals, Inc.NASDAQ: ANIP
Income Tax Expense · Q1 FY2026 · quarter ended Mar 2026
Income tax expense grows, but more slowly than its trailing trend
Q1 FY2026 income tax expense of $10.73M rose 149.2% year over year, behind the +466.7% change in trailing-twelve-month income tax expense. Sequentially, it rose 169.0% from the prior quarter.
Context
- Income tax expense amounted to 2.0% of revenue in FY2025, up 1.4 pp from a year earlier.
- Income tax expense increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +149.2% toward the trailing-twelve-month pace of +466.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Income Tax Expense history
USD · from the income statement
- Latest · FY2025
- 17.45M USD
- Year-over-year change
- +573.0%
| Period | Period end | Income Tax Expense | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 17.45M | +573.0% |
| FY2024 | 2024-12-31 | (3.69M) | -437.6% |
| FY2023 | 2023-12-31 | 1.09M | +107.4% |
| FY2022 | 2022-12-31 | (14.77M) | -9.8% |
| FY2021 | 2021-12-31 | (13.46M) | — |
Income Tax Expense vs competitors
How ANIP compares with its peers on the latest reported figures
- Peers report in different currencies, so income tax expense is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +466.7% is the 2nd highest of 10, against a peer median of +10.8%.
- Income tax expense amounts to 2.6% of revenue for ANIP, versus a peer median of 1.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | ₹7.64B INR | -57.4% | -5.3% | 2.3% | |
| LTM Jun 2026 | $361M USD | +54.9% | +43.8% | 3.3% | |
| LTM Mar 2026 | $33.29M USD | +57.2% | — | 4.2% | |
| LTM Mar 2026 | $23.88M USD | +466.7% | — | 2.6% | |
| LTM Mar 2026 | $23.59M USD | -24.2% | +2.8% | 3.3% | |
| LTM Jun 2026 | $12M USD | -87.1% | — | 0.1% | |
| LTM Mar 2026 | $3.8M USD | +2257.8% | +257.1% | 1.4% | |
| LTM Mar 2026 | $861K USD | +25.0% | +92.4% | 0.3% | |
| LTM Mar 2026 | $413K USD | — | — | 0.3% | |
| LTM Jun 2026 | -$14.14M USD | -137.2% | +19.2% | 0.5% | |
| LTM Jun 2026 | -$251.5M USD | +10.8% | — | 1.7% | |
| Peer median (excluding ANIP) | — | +10.8% | +31.5% | 1.6% | |
Competitors are the stored peer set for ANIP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 216.14M | 316.39M | 486.82M | 614.38M | 883.37M |
| Cost of Revenue | 100.61M | 138.79M | 181.51M | 250.21M | 432.73M |
| Gross Profit | 115.53M | 177.6M | 305.3M | 364.17M | 450.64M |
| Gross Margin | 53.5% | 56.1% | 62.7% | 59.3% | 51.0% |
| Research & Development | 11.37M | 22.32M | 34.29M | 44.58M | 51.66M |
| Selling, General & Admin | 84.29M | 124.04M | 161.7M | 249.64M | 317.75M |
| Operating Expenses | 155.32M | 212.88M | 258.33M | 363.58M | 369.41M |
| Depreciation & Amortization | 47.25M | 59.65M | 59.79M | 67.73M | 91.42M |
| EBITDA | 3.12M | 25.04M | 106.6M | 63.12M | 207.27M |
| EBITDA Margin | 1.4% | 7.9% | 21.9% | 10.3% | 23.5% |
| Operating Income | (39.79M) | (35.28M) | 46.97M | 584K | 81.23M |
| Operating Margin | -18.4% | -11.2% | 9.6% | 0.1% | 9.2% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 11.92M | 28.05M | 26.94M | 17.6M | 20.06M |
| Other Income / Expenses | (16.27M) | (27.38M) | (27.1M) | (22.8M) | 14.56M |
| Income Before Tax | (56.06M) | (62.67M) | 19.87M | (22.21M) | 95.79M |
| Pre-Tax Margin | -25.9% | -19.8% | 4.1% | -3.6% | 10.8% |
| Income Tax Expense | (13.46M) | (14.77M) | 1.09M | (3.69M) | 17.45M |
| Net Income | (42.6M) | (47.9M) | 18.78M | (18.52M) | 78.34M |
| Net Margin | -19.7% | -15.1% | 3.9% | -3.0% | 8.9% |
| EPS (Basic) | (3.40) | (3.05) | 0.95 | (1.04) | 3.50 |
| EPS (Diluted) | (3.40) | (3.05) | 0.94 | (1.04) | 3.32 |
| Weighted Avg Shares | 12.6M | 16.26M | 18M | 19.32M | 20.05M |
| Weighted Avg Shares (Diluted) | 12.6M | 16.26M | 18.19M | 19.32M | 21.23M |
ANI Pharmaceuticals, Inc.
NASDAQ:ANIP
Intrinsic Alpha fair value
Locked
Current Price
$71.47
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.